Global PEGylated Protein Therapeutics Market Expected to Reach $17,813 Million, by 2025

According to a new report published by Allied Market Research, titled, " PEGylated Protein Therapeutics Market by Product Type, Application, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $10,388 million in 2017, and is projected to reach $17,813 million by 2025, growing at a CAGR of 6.9% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.

The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.

By product type, the colony stimulating factor segment accounted for nearly half share of the global occupational medicine market in 2017. Furthermore, the cancer segment is anticipated to grow at the highest rate of 7.4% during the forecast period.

Key Findings of the PEGylated Protein Therapeutics Market:

• North America occupied nearly two-thirds share of the global PEGylated protein therapeutics market in 2017
• The cancer segment is anticipated to grow with the highest CAGR throughout the forecast period.
• Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, owing to FDA approval and launch of new drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR of 7.4% from 2018 to 2025, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward chronic disorders.

The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A.